AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024 ...Middle East

PR Newswire - News
AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024
Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy targeting LN and SLE ROCKVILLE, Md., Nov. 16, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and...

Hence then, the article about abelzeta presents preclinical data from study of c car168 for the treatment of autoimmune diseases at acr convergence 2024 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024 )

Apple Storegoogle play

Last updated :

Also on site :